EU Policy For Devices With Human Blood Derivatives Approaches Completion
This article was originally published in The Gray Sheet
Manufacturers of devices incorporating human blood or blood plasma derivatives would need to obtain approval from the European Medicinal Evaluation Agency before affixing the CE mark, under a plan to amend the EU Medical Device Directive.
You may also be interested in...
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
Resilience has raised $800m to develop new technologies to manufacture complex drugs including vaccines, cell therapies and gene therapies.